Evaluating Glutamatergic Transmission in Schizophrenia

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 113-118

  Tamminga, Carol A ^a   Lahti, Adrienne C ^b   Medoff, Deborah R ^b   Gao, Xue Min ^b   Holcomb, Henry H ^b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

Glutamatergic system; Ketamine; MK 801; Molecular targets; PCP; Psychosis; Schizophrenia

Indexed keywords

AMPHETAMINE; CYCLOSERINE; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PSYCHEDELIC AGENT;

BEHAVIOR; BRAIN REGION; CEREBELLUM; CEREBROSPINAL FLUID LEVEL; CINGULATE GYRUS; COGNITION; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; ELECTROENCEPHALOGRAM; EVALUATION; FRONTAL CORTEX; GENE ACTIVATION; HALLUCINATION; HIPPOCAMPUS; HUMAN; IMMEDIATE EARLY GENE; LIMBIC CORTEX; MOLECULAR BIOLOGY; NERVE CELL; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PARANOIA; PATHOPHYSIOLOGY; SCHIZOPHRENIA; THOUGHT DISORDER;

ANIMALIA;

EID: 0347722467     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.062     Document Type: Conference Paper

References (31)

1. TAMMINGA, C.A., G.K. THAKER & D.R. MEDOFF. 2002. Neuropsychiatric aspects of schizophrenia. In The American Psychiatric Publishing Textbook of Neuropsychiatry and Clinical Neurosciences. 4th edit. S.C. Yudofsky & R.E. Hales, Eds.: 989-1020. American Psychiatric Publishing, Inc. Washington, D.C.
2. HARRISON, P.J. 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (Pt 4): 593-624.
3. ANDREASEN, N.C. 1991. Schizophrenia: the characteristic symptoms [Review]. Schizophr. Bull. 17: 27-49.
4. DELAY, J. & P. DENIKER. 1952. Le'traitement des psychoses par une methode neurolytique derivee de l'hibernotherapie. In Congres des Medecins Alienistes et Neurologistes de France: 497-502. Luxembourg.
5. CARLSSON, A. & M. LINDQUIST. 1963. Effect of chlorpromazine and haloperidol of formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol.: 140-144.
6. SNYDER, S.H. 1972. Catecholamines in the brain as mediators of amphetamine psychosis. Arch. Gen. Psychiatry 27: 169-179.
7. LARUELLE, M., A. ABI-DARGHAM, R. GIL, et al. 1999. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46: 56-72.
8. MELTZER, H.Y. 1995. Role of serotonin in the action of atypical antipsychotic drugs [Review]. Clin. Neurosci. 3: 64-75.
9. NEMEROFF, C.B., W.W. YOUNGBLOOD, P.J. MANBERG, et al. 1983. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 221: 972-975.
10. BENES, F.M., S.L. VINCENT, A. MARIE & Y. KHAN. 1996. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75: 1021-1031.
11. KIM, J.S., H.H. KORNHUBER, W. SCHMID-BURGK & B. HOLZMULLER. 1980. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20: 379-382.
12. ALTSHULER, L.L., M.F. CASANOVA, T.E. GOLDBERG & J.E. KLEINMAN. 1990. The hippocampus and para-hippocampus in schizophrenic, suicide, and control brains. Arch. Gen. Psychiatry 47: 1029-1034.
13. ANIS, N.A., S.C. BERRY, N.R. BURTON & D. LODGE. 1983. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-D-aspartate. Br. J. Pharmacol. 79: 565-575.
14. MONYER, H., N. BURNASHEV, D.J. LAURIE, et al. 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529-540.
15. TAMMINGA, C.A. 1998. Schizophrenia and glutamatergic transmission. Crit. Rev. Neurobiol. 12: 21-36.
16. TSAI, G. & J.T. COYLE. 2002. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42: 165-179.
17. OLNEY, J.W. & N.B. FARBER. 1995. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52: 998-1007.
18. TAMMINGA, C.A., K. TANIMOTO, S. KUO, et al. 1987. PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1: 497-504.
19. GAO, X.M. & C.A. TAMMINGA. 1996. Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48 hour time course. Synapse 23: 274-279.
20. KRYSTAL, J.H., L.P. KARPER, J.P. SEIBYL, et al. 1994. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51: 199-214.
21. MALHOTRA, A.K., D.A. PINALS, C.M. ADLER, et al. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
22. LAHTI, A.C., H.H. HOLCOMB, D.R. MEDOFF & C.A. TAMMINGA. 1995. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6: 869-872.
23. LAHTI, A.C., B. KOFFEL, D. LAPORTE & C.A. TAMMINGA. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
24. LAHTI, A.C., M.A. WEILER, T. MICHAELIDIS, et al. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
25. LAHTI, A.C., D. WARFEL, T. MICHAELIDIS, M.A. WEILER, et al. 2001. Long-term outcome of patients who receive ketamine during research. Biol. Psychiatry 49: 869-875.
26. HOLCOMB, H.H., A.C. LAHTI, D.R. MEDOFF, et al. 2001. Sequential regional cerebral blood flow brain scans using pet with H(2)(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 25: 165-172.
27. MEDOFF, D.R., H.H. HOLCOMB, A.C. LAHTI & C.A. TAMMINGA. 2001. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11: 543-550.
28. SCHWARCZ, R., A. RASSOULPOUR, H.Q. WU, et al. 2001. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50: 521-530.
29. TSAI, G., D.C. GOFF, R.W. CHANG, et al. 1998. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry 155: 1207-1213.
30. HECKERS, S., D. GOFF, D.L. SCHACTER, et al. 1999. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch. Gen. Psychiatry 56: 1117-1123.
31. CASEY, D.E. et al. 2003. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28: 182-192.